EGFR and head and neck squamous cell carcinoma: In HNSCC, tyrosine kinase inhibitors (TKIs) are generally quinazoline-derived, low molecular weight synthetic molecules that competitively block the intracellular ATP binding domain of EGFR and consequently inhibit the activation and phosphorylation of EGFR and its downstream cellular intermediates [36,37].